The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Comparing phase 3 “go” decisions (Ph3-GO) between single arm trials with real-world external control (SAT+rwEC) versus randomized phase 2 trials (rPh2).
 
Brian Hobbs
Stock and Other Ownership Interests - Presagia
Consulting or Advisory Role - Bayer; STCube Pharmaceuticals Inc.
Research Funding - Amgen
(OPTIONAL) Uncompensated Relationships - Presagia
 
Thanh Ton
Employment - Genentech/Roche
Stock and Other Ownership Interests - Genentech/Roche
Travel, Accommodations, Expenses - Genentech/Roche
 
Xiao Li
Employment - Genentech
Stock and Other Ownership Interests - Roche
 
David S. Hong
Stock and Other Ownership Interests - MolecularMatch; OncoResponse; Presagia
Consulting or Advisory Role - Acuta; Adaptimmune; Alphasights; Amgen; Axiom Biotechnologies; Baxter; Bayer; Boxer Capital; COG; EcoR1 Capital; Genentech; Gerson Lehrman Group; GroupH; GroupH; Guidepoint Global; H.C. Wainwright & Co.; HCW Precision; Infinity Pharmaceuticals; Infinity Pharmaceuticals; Janssen; Medscape; Merrimack; Numab; Pfizer; Prime Oncology; Seagen; ST Cube; Takeda; Tavistock Life Sciences; Trieza Therapeutics; WebMD; WebMD
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Aldai Norte (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); BMS (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Erasca, Inc (Inst); Fate Therapeutics (Inst); Genentech (Inst); Genmab (Inst); Ignyta (Inst); Infinity Pharmaceuticals (Inst); Kite, a Gilead company (Inst); Kyowa (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); miRNA Therapeutics (Inst); Molecular Templates (Inst); Mologen (Inst); National Cancer Institute (Inst); Navire (Inst); Novartis (Inst); Numab (Inst); Pfizer (Inst); Seagen (Inst); Takeda (Inst); Turning Point Therapeutics (Inst); Verastem (Inst); VM Pharma (Inst)
Travel, Accommodations, Expenses - AACR; ASCO; Bayer Schering Pharma; Genmab; Loxo; miRNA Therapeutics; Society for Immunotherapy of Cancer
 
Rebecca A. Hubbard
Research Funding - Johnson & Johnson (Inst); Merck (Inst); Pfizer (Inst)
 
Pam K. Mangat
No Relationships to Disclose
 
William Capra
Employment - Genentech
Stock and Other Ownership Interests - Roche
Research Funding - Genentech/Roche
Travel, Accommodations, Expenses - Genentech/Roche
 
Shengchun Kong
Employment - Roche
Stock and Other Ownership Interests - Roche
 
Herbert Pang
Employment - Genentech/Roche
Stock and Other Ownership Interests - Roche
Patents, Royalties, Other Intellectual Property - Methods of developing a prognosis for pancreatic cancer and predicting responsiveness to cancer therapeutics US Patent 10,613,091
Travel, Accommodations, Expenses - Genentech/Roche
 
Meghna Samant
Employment - Flatiron Health
Stock and Other Ownership Interests - Moderna Therapeutics; Roche
Research Funding - Flatiron Health
 
Brian D. Segal
Employment - Flatiron Health
Stock and Other Ownership Interests - Flatiron Health; Roche
 
Liz Garrett-Mayer
Consulting or Advisory Role - Deciphera; TYME